{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:57:12Z","timestamp":1791341832779,"version":"4.3.1"},"reference-count":34,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Abuse"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>Background: In the United States, methadone for treatment of opioid use disorder is dispensed via highly-regulated accredited opioid treatment programs (OTP). During the COVID-19 pandemic, federal regulations were loosened, allowing for greater use of take-home methadone doses. We sought to understand how OTP leaders responded to these policy changes. Methods: We distributed a multistate electronic survey from September to November 2020 of OTP leadership to members\u00a0of the American Association for the Treatment of Opioid Dependence (AATOD) who self-identified as leaders of OTPs. We asked study participants about how their OTP(s) implemented COVID-19-related policy changes into their clinical practice focusing on provision of take-home methadone doses, factors used to determine patient stability, and potential concerns about increased take-home doses. We used Chi-square test to compare survey responses between characterizations of the OTPs. Results: Of 170 survey respondents (17% response rate), the majority represented leadership of for-profit OTPs (69%) and were in a Southern state (54%). Routine allowances and practices related to take-home methadone doses varied across OTPs during the COVID-19 pandemic: 80 (47%) reported 14 days for newly enrolled patients (within past 90 days), 89 (52%) reported 14 days for \u201cless stable\u201d patients, and 112 (66%) reported 28 days for \u201cstable\u201d patients. Conclusions: We found that not all eligible OTP leaders adopted the practice of routinely allowing newly enrolled, \u201cless stable,\u201d and \u201cstable\u201d patients on methadone to have increased take-home doses up to the limit allowed by federal regulations during COVID-19. The pandemic provides an opportunity to critically re-evaluate long-established methadone and OTP regulations in preparation for future emergencies.<\/jats:p>","DOI":"10.1080\/08897077.2021.1986768","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T19:23:18Z","timestamp":1634757798000},"page":"633-639","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":44,"title":["COVID-19-Related Policy Changes for Methadone Take-Home Dosing: A Multistate Survey of Opioid Treatment Program Leadership"],"prefix":"10.1177","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4919-7492","authenticated-orcid":false,"given":"Ximena A.","family":"Levander","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of General Internal Medicine and Geriatrics, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5394-609X","authenticated-orcid":false,"given":"Jarratt D.","family":"Pytell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4117-5961","authenticated-orcid":false,"given":"Kenneth B.","family":"Stoller","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5556-3597","authenticated-orcid":false,"given":"P. Todd","family":"Korthuis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of General Internal Medicine and Geriatrics, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2216-6330","authenticated-orcid":false,"given":"Geetanjali","family":"Chander","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA"},{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,1,1]]},"reference":[{"key":"bibr1-08897077.2021.1986768","unstructured":"Substance Abuse and Mental Health Services Administration. Opioid treatment program (OTP) guidance. Substance Abuse and Mental Health Services Administration; 2020. https:\/\/www.samhsa.gov\/sites\/default\/files\/otp-guidance-20200316.pdf."},{"key":"bibr2-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-05721-5"},{"key":"bibr3-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1803982"},{"key":"bibr4-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.1511"},{"key":"bibr5-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.01.020"},{"key":"bibr6-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-018-4801-3"},{"key":"bibr7-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107968"},{"key":"bibr8-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1177\/1073110518782951"},{"key":"bibr9-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.1624"},{"key":"bibr10-08897077.2021.1986768","unstructured":"Centers for Disease Control and Prevention. Overdose deaths accelerating during COVID-19. Health Alert Network Advisory. https:\/\/www.cdc.gov\/media\/releases\/2020\/p1218-overdose-deaths-covid-19.html. Published December 2020. Accessed February 10, 2021."},{"key":"bibr11-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000841"},{"key":"bibr12-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108008"},{"key":"bibr13-08897077.2021.1986768","unstructured":"U.S. Government Accountability Office. Methadone-Associated Overdose Deaths: Factors Contributing to Increased Deaths and Efforts to Prevent Them; 2009. GAO-09-341. www.gao.gov\/assets\/gao-09-341.pdf. Accessed May 28, 2021."},{"key":"bibr14-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0b013e3181e6ad48"},{"key":"bibr15-08897077.2021.1986768","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Federal Guidelines for Opioid Treatment Programs. Rockville, MD: U.S. Department of Health and Human Services; 2015."},{"key":"bibr16-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103127"},{"key":"bibr17-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1097\/adm.0000000000000812"},{"key":"bibr18-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108449"},{"key":"bibr19-08897077.2021.1986768","unstructured":"American Association for the Treatment of Opioid Dependence, Inc. (AATOD). Our board of directors. http:\/\/www.aatod.org\/about-us\/our-board-of-directors\/. Accessed June 4, 2021."},{"key":"bibr20-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"bibr21-08897077.2021.1986768","unstructured":"Substance Abuse and Mental Health Services Administration. Opioid Treatment Program (OTP) Guidance; 2020. https:\/\/www.samhsa.gov\/sites\/default\/files\/otp-guidance-20200316.pdf. Updated March 29, 2020. Accessed May 28, 2020."},{"issue":"3","key":"bibr22-08897077.2021.1986768","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.2517-6161.1968.tb00759.x","volume":"30","author":"Hope ACA.","year":"1968","journal-title":"J R Stat Soc"},{"key":"bibr23-08897077.2021.1986768","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020."},{"key":"bibr24-08897077.2021.1986768","unstructured":"Bryer J, Speerschneider K. Likert: analysis and visualization likert items. R package version 1.3.5; 2016."},{"key":"bibr25-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.28557"},{"key":"bibr26-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108197"},{"key":"bibr27-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108328"},{"key":"bibr28-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000608"},{"key":"bibr29-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2020.01472"},{"key":"bibr30-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108288"},{"key":"bibr31-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108223"},{"key":"bibr32-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.202000226"},{"key":"bibr33-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.08.011"},{"key":"bibr34-08897077.2021.1986768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108219"}],"container-title":["Substance Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2021.1986768","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1080\/08897077.2021.1986768","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2021.1986768","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:55:52Z","timestamp":1777625752000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/08897077.2021.1986768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1080\/08897077.2021.1986768"],"URL":"https:\/\/doi.org\/10.1080\/08897077.2021.1986768","relation":{},"ISSN":["0889-7077","1547-0164"],"issn-type":[{"value":"0889-7077","type":"print"},{"value":"1547-0164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}